Stay updated on MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial page.

Latest updates to the MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial page
- Check2 days agoChange DetectedRevision: v3.3.4 replaces the previous v3.3.3 label on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedLocations section updated to consolidate all study sites under a single 'Locations' heading, adding California, Connecticut, Florida, Illinois, Maryland, New York, Ohio, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, and Quebec. Individual state location headings were removed in favor of a unified Locations list.SummaryDifference1%

- Check53 days agoChange DetectedThe page now displays revision label v3.3.2 and the previous v3.2.0 label is removed.SummaryDifference0.0%

- Check60 days agoChange DetectedThe notice about government funding and data currency was removed from the page. No new content was added.SummaryDifference0.3%

- Check81 days agoChange DetectedThe Study Details page shows only minor formatting adjustments with no changes to core study content, including eligibility criteria, outcomes, or listed locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check103 days agoChange DetectedAdded a government-operating-status notice and a new version tag (v3.2.0) while removing the old version tag (v3.1.0).SummaryDifference1%

Stay in the know with updates to MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MEDI4736 and Tremelimumab in Gastric Cancer Clinical Trial page.